PMC:7402624 / 60028-60278 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T507","span":{"begin":31,"end":41},"obj":"Body_part"},{"id":"T508","span":{"begin":236,"end":240},"obj":"Body_part"}],"attributes":[{"id":"A507","pred":"fma_id","subj":"T507","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A508","pred":"fma_id","subj":"T508","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Immunotype 3, in which minimal lymphocyte activation response was observed, may represent ~20% of COVID-19 patients and is a potentially important scenario to consider as patients who may have failed to mount a robust antiviral T and B cell response."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1918","span":{"begin":107,"end":115},"obj":"Species"},{"id":"1919","span":{"begin":171,"end":179},"obj":"Species"},{"id":"1925","span":{"begin":98,"end":106},"obj":"Disease"}],"attributes":[{"id":"A1918","pred":"tao:has_database_id","subj":"1918","obj":"Tax:9606"},{"id":"A1919","pred":"tao:has_database_id","subj":"1919","obj":"Tax:9606"},{"id":"A1925","pred":"tao:has_database_id","subj":"1925","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Immunotype 3, in which minimal lymphocyte activation response was observed, may represent ~20% of COVID-19 patients and is a potentially important scenario to consider as patients who may have failed to mount a robust antiviral T and B cell response."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T405","span":{"begin":98,"end":106},"obj":"Disease"}],"attributes":[{"id":"A405","pred":"mondo_id","subj":"T405","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Immunotype 3, in which minimal lymphocyte activation response was observed, may represent ~20% of COVID-19 patients and is a potentially important scenario to consider as patients who may have failed to mount a robust antiviral T and B cell response."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T916","span":{"begin":42,"end":52},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T917","span":{"begin":123,"end":124},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T918","span":{"begin":209,"end":210},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T919","span":{"begin":234,"end":240},"obj":"http://purl.obolibrary.org/obo/CL_0000236"}],"text":"Immunotype 3, in which minimal lymphocyte activation response was observed, may represent ~20% of COVID-19 patients and is a potentially important scenario to consider as patients who may have failed to mount a robust antiviral T and B cell response."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T20552","span":{"begin":218,"end":227},"obj":"Chemical"}],"attributes":[{"id":"A88463","pred":"chebi_id","subj":"T20552","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"Immunotype 3, in which minimal lymphocyte activation response was observed, may represent ~20% of COVID-19 patients and is a potentially important scenario to consider as patients who may have failed to mount a robust antiviral T and B cell response."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T126","span":{"begin":31,"end":52},"obj":"http://purl.obolibrary.org/obo/GO_0046649"}],"text":"Immunotype 3, in which minimal lymphocyte activation response was observed, may represent ~20% of COVID-19 patients and is a potentially important scenario to consider as patients who may have failed to mount a robust antiviral T and B cell response."}

{"project":"LitCovid-sentences","denotations":[{"id":"T348","span":{"begin":0,"end":250},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Immunotype 3, in which minimal lymphocyte activation response was observed, may represent ~20% of COVID-19 patients and is a potentially important scenario to consider as patients who may have failed to mount a robust antiviral T and B cell response."}